Abstract
The Italian pharmaceutical chemical maker Dipharma has struck a deal to acquire Kalexsyn, a Kalamazoo, Mich.-based provider of contract research services. Dipharma says the purchase will mesh Kalexsyn’s ability to carry out difficult syntheses of molecules for preclinical drug studies with its commercial manufacturing skills. Dipharma plans to install equipment allowing Kalexsyn to make larger volumes of molecules for clinical trials. Kalexsyn was formed in 2003 by two former Pfizer chemists.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
